Patents by Inventor Steve Cosgrove

Steve Cosgrove has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACALABRUTINIB MALEATE DOSAGE FORMS
    Publication number: 20230226049
    Abstract: The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Paul BETHEL, John BLYTH, Steve COSGROVE, Michael GOLDEN, James MANN, Xavier Jacques Henri PEPIN, Andrew ROBBINS, David SIMPSON
  • Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound
    Publication number: 20070293513
    Abstract: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Type: Application
    Filed: August 24, 2007
    Publication date: December 20, 2007
    Applicant: AstraZeneca AB
    Inventors: Martin Bohlin, Steve Cosgrove, Bo Lassen
  • Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
    Patent number: 7265124
    Abstract: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms of a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: September 4, 2007
    Assignee: AstraZeneca AB
    Inventors: Martin Bohlin, Steve Cosgrove, Bo Lassen
  • CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND
    Publication number: 20070173518
    Abstract: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms of a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Type: Application
    Filed: October 3, 2005
    Publication date: July 26, 2007
    Applicant: AstraZeneca AB
    Inventors: Martin Bohlin, Steve Cosgrove, Bo Lassen
  • Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
    Publication number: 20030181469
    Abstract: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Type: Application
    Filed: December 2, 2002
    Publication date: September 25, 2003
    Inventors: Martin Bohlin, Steve Cosgrove, Bo Lassen